Dr. Julie Lemieux is a hemato-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and clinical professor at the Laval University School of Medicine. Dr. Lemieux is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.

Dr. Lemieux is a member of the Canadian Clinical Trial Group for quality of life in breast cancer. She is also a scientific committee member for the McPeak-Sirois research group.

Using structured breast cancer data
The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and monitoring of cancers and benign breast diseases.

Offer innovative treatments
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.

Support the quality of life
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life despite the adverse effects of the disease on an individual’s life.

Hôpital Saint-Sacrement
1050, chemin Sainte-Foy
J0-14
Québec, Québec
Canada G1S 4L8
60 entries « 2 of 6 »

Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Journal Article

Lancet Oncol, 22 (2), 2021.

Abstract | Links:

Goodwin PJ, Dowling RJO, Ennis M, Chen BE, Parulekar WR, Shepherd LE, Gelmon KA, Whelan TJ, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Rastogi P, Rabaglio-Poretti M, Lemieux J, Thompson AM, Rea DW, Stambolic V

Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo

Journal Article

JNCI Cancer Spectr, 5 (5), 2021.

Abstract | Links:

Roy V, Ruel S, Ivers H, Savard MH, Gouin JP, Caplette-Gingras A, Lemieux J, Couture F, Savard J

Stress-buffering effect of social support on immunity and infectious risk during chemotherapy for breast cancer

Journal Article

Brain Behav Immun Health, 10 , 2021.

Abstract | Links:

Morin-Buote J, Ennour-Idrissi K, Poirier É, Lemieux J, Furrer D, Burguin A, Durocher F, Diorio C

Association of Breast Tumour Expression of Cannabinoid Receptors CBR1 and CBR2 with Prognostic Factors and Survival in Breast Cancer Patients

Journal Article

J Pers Med, 11 (9), 2021.

Abstract | Links:

Pimentel I, Chen BE, Lohmann AE, Ennis M, Ligibel J, Shepherd L, Hershman DL, Whelan T, Stambolic V, Mayer I, Hobday T, Lemieux J, Thompson A, Rastogi P, Gelmon K, Rea D, Rabaglio M, Ellard S, Mates M, Bedard P, Pitre L, Vandenberg T, Dowling RJO, Parulekar W, Goodwin PJ

The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32

Journal Article

J Natl Cancer Inst, 113 (2), 2021.

Abstract | Links:

Gagnet S, Diorio C, Provencher L, Mbuya-Bienge C, Lapointe J, Morin C, Lemieux J, Nabi H

Identifying Clinicopathological Factors Associated with Oncotype DX® 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada

Journal Article

J Pers Med, 11 (9), 2021.

Abstract | Links:

Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O'Shaughnessy J,

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

Journal Article

Eur J Cancer, 152 , 2021.

Abstract | Links:

Nixon NA, Simmons C, Lemieux J, Verma S

Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership

Journal Article

Breast J, 26 (3), 2020.

Abstract | Links:

Labonte M, Guillaumie L, Dionne A, Dorval M, Nabi H, Lemieux J, Provencher L, Lauzier S

Development of a community pharmacy-based intervention to enhance adherence to adjuvant endocrine therapy among breast cancer survivors guided by the Intervention Mapping approach

Journal Article

Res Social Adm Pharm, 16 (12), 2020.

Abstract | Links:

Oudanonh T, Nabi H, Ennour-Idrissi K, Lemieux J, Diorio C

Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer

Journal Article

Int J Cancer, 146 (10), 2020.

Abstract | Links:

60 entries « 2 of 6 »
Signaler des ajouts ou des modifications

Active projects

  • Age-related patterns in the experience of chemotherapy-induced peripheral neuropathy, from 2019-10-01 to 2024-09-30
  • Elucidating patient and healthcare practitioner decision-making about chemotherapy-induced peripheral neuropathy-related, from 2023-04-01 to 2027-03-31
  • Favoriser l'engagement des femmes ayant eu un cancer du sein dans les décisions concernant l'hormonothérapie adjuvante prolongée, from 2023-10-01 to 2027-05-31
  • NSABP Breast Cancer Treatment Protocols, from 1997-02-01 to 2025-12-25
  • PALbociclib CoLlaborative Adjuvant Study (PALLAS study), from 2017-05-17 to 2025-12-25
  • Perfectionism and psychosocial adjustment to cancer : A mixed methods study, from 2020-03-31 to 2024-03-31
  • Personalized risk-stratified breast cancer follow-up care: a feasibility and acceptability study, from 2023-06-26 to 2026-06-30
  • Pour des soins en oncologie inclusifs: Améliorer le parcours et l'expérience de soins des personnes des minorités sexuelles et de genre, from 2023-12-13 to 2025-12-12
  • TBC1D9: therapeutic target of the aggressiveness of triple negative breast cancer, from 2023-03-01 to 2024-02-29
  • The effect of cannabinoid receptors on breast cancer survival, from 2022-09-01 to 2024-08-31
  • Vers des trajectoires de soins en cancer du sein personnalisées en fonction du risque et des besoins des patientes: une étude de faisabilité et d'acceptabilité, from 2023-04-01 to 2025-03-31

Recently finished projects

  • Exploring the impact for COVID-19 pandemic on women with breast cancer in Quebec, from 2021-12-01 to 2023-09-30
  • Projet pilote de l'utilisation d'une application pour le suivi et la prise en charge des effets secondaires associés aux traitements anti-néoplasiques oraux chez les patientes avec cancer du sein, from 2021-08-01 to 2023-07-31
  • Une infrastructure IA multi-usagers clé en main pour gérer le cycle de vie complet des données en santé, from 2021-04-01 to 2023-12-01
Data provided by the Université Laval research projects registery